{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:00:11Z","timestamp":1789207211659,"version":"build-2803163510"},"reference-count":60,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,5]]},"abstract":"<jats:p>The role of <jats:italic>Dientamoeba fragilis<\/jats:italic> in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of <jats:italic>D. fragilis<\/jats:italic> alleviates symptoms in IBS. Twenty-five <jats:italic>D. fragilis-<\/jats:italic>positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between <jats:italic>D. fragilis<\/jats:italic> and IBS. Some <jats:italic>D. fragilis<\/jats:italic>-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of <jats:italic>D. fragilis<\/jats:italic> in IBS and into efficient treatments of <jats:italic>D. fragilis<\/jats:italic> are warranted.<\/jats:p>","DOI":"10.4269\/ajtmh.2012.11-0761","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T06:08:25Z","timestamp":1350972505000},"page":"1046-1052","source":"Crossref","is-referenced-by-count":33,"title":["Treatment of Dientamoeba fragilis in Patients with Irritable Bowel Syndrome"],"prefix":"10.4269","volume":"87","author":[{"given":"Anne Line","family":"Engsbro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Rune","family":"Stensvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik V.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bytzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Gastroenterol Clin North Am","first-page":"1","article-title":"Epidemiology of IBS","volume":"40","author":"Choung","year":"2011"},{"key":"R2","series-title":"Curr Gastroenterol Rep","first-page":"265","article-title":"The burden of IBS: looking at metrics","volume":"11","author":"Spiegel","year":"2009"},{"key":"R3","series-title":"Gastroenterology","first-page":"1480","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006"},{"key":"R4","series-title":"Aliment Pharmacol Ther","first-page":"1171","article-title":"Health-related quality of life among persons with irritable bowel syndrome: a systematic review","volume":"16","author":"El-Serag","year":"2002"},{"key":"R5","series-title":"Gastroenterol Clin North Am","first-page":"11","article-title":"The effect of irritable bowel syndrome on health-related quality of life and health care expenditures","volume":"40","author":"Agarwal","year":"2011"},{"key":"R6","series-title":"Eur J Gastroenterol Hepatol","first-page":"S11","article-title":"Systematic review on the management of irritable bowel syndrome in the European Union","volume":"19","author":"Quigley","year":"2007"},{"key":"R7","series-title":"Dig Liver Dis","first-page":"717","article-title":"Irritable bowel syndrome: the burden and unmet needs in Europe","volume":"38","author":"Quigley","year":"2006"},{"key":"R8","series-title":"Aliment Pharmacol Ther","first-page":"535","article-title":"Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome","volume":"26","author":"Thabane","year":"2007"},{"issue":"(Suppl 3)","key":"R9","series-title":"J Gastroenterol Hepatol","first-page":"94","article-title":"Post-infectious irritable bowel syndrome: the past, the present and the future","volume":"26","author":"Ghoshal","year":"2011"},{"key":"R10","series-title":"Gut","first-page":"997","article-title":"An irritable bowel syndrome subtype defined by species-specific alterations in fecal microbiota","volume":"61","author":"Jeffery","year":"2011"},{"key":"R11","series-title":"Microbiology","first-page":"3205","article-title":"Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives","volume":"156","author":"Salonen","year":"2010"},{"key":"R12","series-title":"Gastroenterology","first-page":"1792","article-title":"Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome","volume":"141","author":"Rajilic-Stojanovic","year":"2011"},{"key":"R13","series-title":"Neurogastroenterol Motil","first-page":"512","article-title":"Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome","volume":"22","author":"Tana","year":"2010"},{"key":"R14","series-title":"Am J Gastroenterol","first-page":"1033","article-title":"The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review","volume":"104","author":"Brenner","year":"2009"},{"key":"R15","series-title":"Adv Med Sci","first-page":"139","article-title":"Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial","volume":"52","author":"Majewski","year":"2007"},{"key":"R16","series-title":"Am J Gastroenterol","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study","volume":"98","author":"Pimentel","year":"2003"},{"key":"R17","series-title":"Ann Intern Med","first-page":"557","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"145","author":"Pimentel","year":"2006"},{"key":"R18","series-title":"Dig Dis Sci","first-page":"1297","article-title":"Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study","volume":"51","author":"Pimentel","year":"2006"},{"key":"R19","series-title":"N Engl J Med","first-page":"22","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011"},{"key":"R20","series-title":"World J Gastroenterol","first-page":"6016","article-title":"Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics","volume":"13","author":"Esposito","year":"2007"},{"key":"R21","series-title":"Am J Gastroenterol","first-page":"28","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012"},{"key":"R22","series-title":"Am J Gastroenterol","first-page":"326","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006"},{"key":"R23","series-title":"Gut Microbes","first-page":"3","article-title":"A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness","volume":"2","author":"Barratt","year":"2011"},{"key":"R24","series-title":"Am J Trop Med Hyg","first-page":"614","article-title":"A review of the clinical presentation of dientamoebiasis","volume":"82","author":"Stark","year":"2010"},{"key":"R25","series-title":"CMAJ","first-page":"468","article-title":"Dientamoeba fragilis: an emerging role in intestinal disease","volume":"175","author":"Lagace-Wiens","year":"2006"},{"key":"R26","series-title":"Clin Microbiol Rev","first-page":"553","article-title":"Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis","volume":"17","author":"Johnson","year":"2004"},{"key":"R27","series-title":"Epidemiol Infect","first-page":"1655","article-title":"Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite","volume":"137","author":"Stensvold","year":"2009"},{"key":"R28","series-title":"Clin Infect Dis","first-page":"280","article-title":"Etiology of gastroenteritis in sentinel general practices in the Netherlands","volume":"33","author":"de Wit","year":"2001"},{"key":"R29","series-title":"Int J Parasitol","first-page":"11","article-title":"Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis","volume":"37","author":"Stark","year":"2007"},{"key":"R30","series-title":"J Clin Microbiol","first-page":"2718","article-title":"Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population","volume":"43","author":"Stark","year":"2005"},{"key":"R31","series-title":"Clin Microbiol Infect","first-page":"110","article-title":"Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole","volume":"9","author":"Girginkardesler","year":"2003"},{"key":"R32","series-title":"Arch Roum Pathol Exp Microbiol","first-page":"49","article-title":"Studies on Dientamoeba fragilis in Romania. II. Incidence of Dientamoeba fragilis in healthy persons","volume":"39","author":"Colea","year":"1980"},{"key":"R33","series-title":"J Gastroenterol Hepatol","first-page":"A103","article-title":"Eradication of Dientamoeba fragilis can resolve IBS-like symptoms","volume":"17","author":"Borody","year":"2002"},{"key":"R34","series-title":"Trends Parasitol","first-page":"92","article-title":"Dientamoebiasis: clinical importance and recent advances","volume":"22","author":"Stark","year":"2006"},{"key":"R35","series-title":"Parasitol Res","first-page":"679","article-title":"Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria","volume":"107","author":"Yakoob","year":"2010"},{"key":"R36","series-title":"Parasitol Res","first-page":"1269","article-title":"Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population","volume":"110","author":"Jimenez-Gonzalez","year":"2012"},{"issue":"(Suppl 3)","key":"R37","series-title":"Gut","first-page":"A58","article-title":"Diagnostic strategies in patients suspected of irritable bowel syndrome","volume":"60","author":"Engsbro","year":"2011"},{"key":"R38","series-title":"Diagn Microbiol Infect Dis","first-page":"303","article-title":"Detecting Blastocystis using parasitologic and DNA-based methods: a comparative study","volume":"59","author":"Stensvold","year":"2007"},{"key":"R39","series-title":"Scand J Infect Dis","first-page":"129","article-title":"The prevalence and clinical significance of intestinal parasites in HIV-infected patients in Denmark","volume":"43","author":"Stensvold","year":"2011"},{"key":"R40","series-title":"Clin Gastroenterol Hepatol","first-page":"534","article-title":"Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints","volume":"5","author":"Camilleri","year":"2007"},{"key":"R41","series-title":"Antimicrob Agents Chemother","first-page":"487","article-title":"In vitro susceptibility testing of Dientamoeba fragilis","volume":"56","author":"Nagata","year":"2012"},{"key":"R42","series-title":"Mol Cell Probes","first-page":"400","article-title":"Real-time PCR for the detection of Dientamoeba fragilis in fecal samples","volume":"21","author":"Verweij","year":"2007"},{"key":"R43","series-title":"Am J Trop Med Hyg","first-page":"16","article-title":"Dientamoeba fragilis: a review with notes on its epidemiology, pathogenicity, mode of transmission, and diagnosis","volume":"26","author":"Yang","year":"1977"},{"key":"R44","series-title":"J Pediatr Gastroenterol Nutr","first-page":"16","article-title":"Dientamoeba fragilis masquerading as allergic colitis","volume":"26","author":"Cuffari","year":"1998"},{"key":"R45","series-title":"Clin Microbiol Infect","first-page":"601","article-title":"A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis","volume":"14","author":"Kurt","year":"2008"},{"key":"R46","series-title":"N Z Med J","first-page":"64","article-title":"Dientamoeba fragilis: a bowel pathogen?","volume":"100","author":"Oxner","year":"1987"},{"key":"R47","series-title":"J Hyg Epidemiol Microbiol Immunol","first-page":"27","article-title":"On the clinical importance of Dientamoeba fragilis infections in childhood","volume":"35","author":"Preiss","year":"1991"},{"key":"R48","series-title":"Clin Gastroenterol Hepatol","first-page":"534","article-title":"Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints","volume":"5","author":"Camilleri","year":"2007"},{"key":"R49","series-title":"Gastroenterology","first-page":"1944","article-title":"Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report","volume":"137","author":"Spiegel","year":"2009"},{"key":"R50","series-title":"Aliment Pharmacol Ther","first-page":"239","article-title":"Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome","volume":"28","author":"Mangel","year":"2008"},{"key":"R51","series-title":"Am J Gastroenterol","first-page":"115","article-title":"A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"Chang","year":"2005"},{"key":"R52","series-title":"Am J Gastroenterol","first-page":"2562","article-title":"Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome","volume":"103","author":"Drossman","year":"2008"},{"key":"R53","series-title":"Ned Tijdschr Geneeskd","first-page":"575","article-title":"Dientamoeba fragilis: possibly an important cause of persistent abdominal pain in children","volume":"148","author":"Bosman","year":"2004"},{"key":"R54","series-title":"Dig Dis Sci","first-page":"1811","article-title":"Dientamoeba fragilis. An unusual intestinal pathogen","volume":"41","author":"Butler","year":"1996"},{"key":"R55","series-title":"Conn Med","first-page":"69","article-title":"Tetracycline treatment of Dientamoeba fragilis","volume":"47","author":"Dardick","year":"1983"},{"key":"R56","series-title":"Dig Dis Sci","first-page":"335","article-title":"Dientamoeba fragilis, a protozoan parasite in adult members of a semicommunal group","volume":"28","author":"Millet","year":"1983"},{"key":"R57","series-title":"Clin Microbiol Infect","first-page":"65","article-title":"Dientamoeba fragilis\u2013a protozoal infection which may cause severe bowel distress","volume":"9","author":"Norberg","year":"2003"},{"key":"R58","series-title":"Am J Dis Child","first-page":"390","article-title":"Dientamoeba fragilis. An intestinal pathogen in children?","volume":"133","author":"Spencer","year":"1979"},{"key":"R59","series-title":"Am J Gastroenterol","first-page":"565","article-title":"Dientamoeba fragilis: a gastrointestinal protozoan infection in adults","volume":"77","author":"Spencer","year":"1982"},{"key":"R60","series-title":"Pediatr Infect Dis J","first-page":"88","article-title":"Treatment of Dientamoeba fragilis infection with paromomycin","volume":"26","author":"Vandenberg","year":"2007"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/87\/6\/article-p1046.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/87\/6\/article-p1046.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/87\/6\/article-p1046.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:12:46Z","timestamp":1723050766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/87\/6\/article-p1046.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":60,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.2012.11-0761","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}